athymia

[ah-thi´me-ah]

1. absence of functioning thymus tissue.

2. lack of feeling and emotion, as found in depression and other mental disorders.

a·thy·mi·a

(ă-thī'mē-ă),

1. Absence of affect or emotivity; morbid impassivity.

2. Congenital absence of the thymus, often with associated immunodeficiency. Synonym(s): athymism

[G. a- priv. + thymos, mind, also thymus]

Farlex Partner Medical Dictionary © Farlex 2012

athymia

Psychiatry
An older term which has been variously used for a disparate range of conditions:
(1) Dementia;
(2) Emotionlessness;
(3) Fainting;
(4) Melancholia, major depressive disorder—recurrent (DSM-IV);
(5) Unconsciousness.

Surgery
(1) Thymic aplasia; absence of thymus.
(2) Status post-thymectomy.

a·thy·mi·a

(ā-thī'mē-ă)

1. psychology Absence of affect or emotion; morbid impassivity.

2. Congenital absence of the thymus, often with associated immunodeficiency.
Synonym(s): athymism.

[G. a- priv. + thymos, mind, also thymus]

Medical Dictionary for the Health Professions and Nursing © Farlex 2012

References in periodicals archive

M2 PHARMA-June 7, 2019-US FDA Accepts Enzyvant Biologics License Application and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

- The US Food and Drug Administration has accepted for filing US-based biopharmaceutical company Enzyvant's Biologics License Application for RVT-802, a novel investigational tissue-based regenerative therapy designed to treat pediatric congenital athymia, and granted Priority Review, the company said.

Congenital athymia is a rare and deadly condition associated with complete DiGeorge Anomaly, CHARGE syndrome, and FOXN1 deficiency.

Children with congenital athymia are born without a thymus, resulting in a severe immunodeficiency due to the inability to produce normally functioning T cells, which defend against infection and regulate essential processes in the immune system.

Approximately 20 infants are born each year in the United States with congenital athymia, which is fatal if untreated.

RVT-802 is a novel investigational tissue-based regenerative therapy designed to treat primary immune deficiency resulting from pediatric congenital athymia. In a healthy, functioning immune system, T cells that start as stem cells in bone marrow become fully developed in the thymus.

US FDA Accepts Enzyvant Biologics License Application and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

It is important to take into consideration that athymia is associated with profound immunodeficiency, but restitution of thymus leads to the improvement of the immune system [67].

(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity

He fulfilled all the Bassett criteria for VCFS except history of hypocalcaemia and athymia.

Jake met all of the Bassett criteria except a history of athymia, hypocalcaemia and hypoparathyroidism.

Velocardiofacial syndrome--a syndrome with many faces

Although a causal relationship between acquired athymia and immune dysregulation has yet to be established, thymectomies in patients younger than 3 months have been shown to result in lower numbers of circulating T cells and diminished responses to T-cell mitogens.[14] Hence, preoperative imaging studies are recommended to verify the presence of mediastinal thymic tissue prior to surgical neck exploration.

Ectopic Cervical Thymic Tissue: Diagnosis by Fine Needle Aspiration

RVT-802 is an investigational, single administration, tissue-based regenerative therapy designed to treat the primary immune deficiency resulting from congenital athymia associated with complete DiGeorge Anomaly (cDGA) which is uniformly fatal if untreated, with death typically occurring in the first 24 months of life due to susceptibility to infection.

Enzyvant Begins Rolling Submission of BLA for Single Administration cDGA Treatment

RVT-802 is an investigational one-time thymic tissue-based regenerative therapy designed to reconstitute the immune system for the treatment of primary immune deficiency resulting from congenital athymia associated with complete DiGeorge Anomaly (cDGA).

Partnership Formed to Advance Research on Regenerative Therapy for Rare DiGeorge Anomaly